MOR23 Promotes Muscle Regeneration and Regulates Cell Adhesion and Migration  by Griffin, Christine A. et al.
Developmental Cell
ArticleMOR23 Promotes Muscle Regeneration
and Regulates Cell Adhesion and Migration
Christine A. Griffin,1,2 Kimberly A. Kafadar,2 and Grace K. Pavlath2,*
1Graduate Program in Biochemistry, Cell and Developmental Biology
2Department of Pharmacology, 1510 Clifton Rd., Room 5027
Emory University, Atlanta, GA 30322, USA
*Correspondence: gpavlat@emory.edu
DOI 10.1016/j.devcel.2009.09.004SUMMARY
Odorant receptors (ORs) in the olfactory epithelium
bind to volatile small molecules leading to the per-
ception of smell. ORs are expressed in many tissues
but their functions are largely unknown. We show
multiple ORs display distinct mRNA expression
patterns during myogenesis in vitro and muscle
regeneration in vivo. Mouse OR23 (MOR23) expres-
sion is induced during muscle regeneration when
muscle cells are extensively fusing and plays a key
role in regulating migration and adhesion of muscle
cells in vitro, two processes common during tissue
repair. A soluble ligand for MOR23 is secreted
by muscle cells in vitro and muscle tissue in vivo.
MOR23 is necessary for proper skeletal muscle
regeneration as loss of MOR23 leads to increased
myofiber branching, commonly associatedwithmus-
cular dystrophy. Together these data identify a func-
tional role for an OR outside of the nose and suggest
a larger role for ORs during tissue repair.
INTRODUCTION
Odorant receptors (ORs) are G protein-coupled receptors
(GPCRs) expressed within the olfactory epithelium of the nose
where they function as chemosensors to detect small molecules
we perceive as smell. ORs are the largest receptor family in
mammals comprising 3%–5% of all genes (Young and Trask,
2002), with approximately 913 potential OR genes in the mouse
genome, and 390 in the human genome (Olender et al., 2008;
Zhang and Firestein, 2002). Microarray analyses suggest ORs
are expressed in many tissues (Feldmesser et al., 2006), but
functions of these receptors are known for only three: chemo-
sensing in olfactory epithelium, proliferation in prostate cancer,
and chemotaxis in sperm of humans and mice (Fukuda et al.,
2004; Neuhaus et al., 2009; Spehr et al., 2003).
One of the ORs that regulates sperm chemotaxis is mouse
olfactory receptor 23 (MOR23, Olfr16) (Fukuda et al., 2004). We
unexpectedly observed an increase in MOR23 expression in
a microarray analysis performed during myogenesis of primary
cultured mouse muscle cells (unpublished data). This increase
occurred when muscle cells were undergoing extensive cell
migration, adhesion, and fusion to form multinucleated cells. InDevelopmadult skeletal muscle, myogenesis occurs to regenerate muscle
after injury. This process is dependent on satellite cells, which
are normally quiescent, but in response to injury proliferate,
and their progeny myoblasts differentiate and fuse with each
other or with existing myofibers to restore normal tissue architec-
ture. Migration and cell-cell adhesion are necessary for muscle
cell differentiation (Kang et al., 2004) and fusion in vitro (Jansen
and Pavlath, 2006). Therefore, identifying the molecules that
control muscle cell adhesion and migration may reveal potential
molecular targets for improving muscle regeneration. As MOR23
regulates migration of sperm, we hypothesized that ORs may
affect similar processes during myogenesis.
Here, we demonstrate that MOR23 is an important regulator of
myogenesis in vitro and in vivo through effects on cell migration
and adhesion, influencing downstream fusion events. In addi-
tion, our data suggest a MOR23 ligand is secreted by muscle
cells in vitro and is also present in muscle tissue. Furthermore,
a number of ORs were also expressed by regenerating muscle,
which may suggest a larger role for ORs in tissue repair.
RESULTS
Multiple ORs, with Distinct Patterns, Are Expressed
During Myogenesis
Multinucleated myofibers form through fusion of muscle cells,
which requires cell migration and adhesion factors (Jansen and
Pavlath, 2008). Myogenesis in vitro occurs in distinct phases
(Figure 1A): proliferating myoblasts terminally differentiate to
become fusion-competent myocytes in differentiation media
(DM). By 24 hr in DM, myocytes fuse with one another to form
small, nascent myotubes with few nuclei. By 48 hr in DM, further
rounds of fusion create mature myotubes with many nuclei. By
microarray analysis, MOR23 mRNA was upregulated at 24 hr
of myogenesis (unpublished data). To validate the expression
of MOR23 and also to determine whether other ORs are
expressed during myogenesis in vitro and in vivo, we performed
Real Time RT-PCR. Given the large numbers of mouse ORs,
we choose 18 ORs previously identified in microarray screens
of skeletal muscle (Beggs et al., 2004; Melcon et al., 2006; Tseng
et al., 2002; Zhao et al., 2002). Olfactory bulb RNA was used as
a positive control for OR mRNA (see Table S1 available online).
Thirteen ORs were expressed during myogenesis (Tables S2
and S3, Figure 1). The majority of ORs expressed in vitro were
most highly expressed at 0 hr, when the muscle cells are prolif-
erating myoblasts (Table S2, Figures 1B and 1C). A smaller
number of ORs were increased with terminal differentiation,ental Cell 17, 649–661, November 17, 2009 ª2009 Elsevier Inc. 649
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fusing. Interestingly, no ORs were upregulated or exclusively
expressed at 48 hr in DM, when most cells have already fused.
Expression of these ORs was also highly regulated during
skeletal muscle regeneration (Table S3, Figures 1D and 1E).
Only one OR was most highly expressed in uninjured muscle
tissue, whereas the majority of ORs were upregulated at day 5
of regeneration, when muscle cells are proliferating, differenti-
ating, and fusing into nascent myofibers. The ORs expressed at
day 5 were those detected at both 0 and 24 hr in vitro. Two
ORs were most highly expressed at day 10 after regeneration,
when most muscle cell fusion had already occurred. The mRNA
for most ORs was expressed both in vitro and in vivo, except
for two. Olfr70 was expressed at very low levels in vitro and
was not apparent in vivo. This discrepancy may be due to prob-
lems with sensitivity of detection or time points chosen in vivo
or may be related to cell culture conditions. Olfr49, expressed
only in vivo, might be expressed by cells other than muscle, or
in a subpopulation of muscle cells that was not retained in vitro.
Together, our results demonstrate multiple ORs display distinct
expression patterns during myogenesis, suggesting that indi-
vidual ORs may have nonredundant functions. ORs increased
after differentiation and during fusion may have similar functions
to ORs in sperm and olfactory neurons, regulating migration or
adhesion. This subset of ORs was of specific interest as they
might have conserved functions in muscle.
MOR23 Is Expressed During Myogenesis and Regulates
Myocyte Migration
To investigate the role of a specific OR, MOR23 was selected, as
its mRNA was upregulated during times of cell fusion and its
expression was verified by use of a second primer pair (Tables
S2 and S3, Figures 1B, 1D, and 2A, Figure S2); similarly, immu-
noblot analysis revealed increased amounts of MOR23 protein at
24 hr in DM (Figure 2B). The MOR23 antibody likely crossreacts
with the closely related olfactory receptor, Olfr1403, which
shares 85% homology to MOR23 and whose mRNA is most
highly expressed in myoblasts (Figures S1A and S1B). Based
on the mRNA expression pattern for Olfr1403, most of the anti-
body reactive band at 24 hr in DM likely reflects MOR23 and
not Olfr1403.
In both olfactory neurons and sperm, activation of ORs leads to
similar downstream signaling events: activation of Gaolf, a G
protein specific to odorant receptors, initiates signal transduction
through membrane adenylyl cyclase III (mACIII) (Spehr et al.,
2004). We observed both isoforms of Gaolf, and mACIII in muscle
cells at 24 hr in DM by immunoblotting (Figure 2B) suggesting that
canonical OR signaling may occur within muscle cells.
Given that MOR23 is upregulated when myocytes are
migrating and fusing, we hypothesized that MOR23 may have
a conserved migratory function in myocytes. Thus, we examined
the migration of myocytes in which MOR23 expression was
knocked down by siRNA. First, to determine efficiency of knock-
down, RNA was isolated from cells retrovirally infected with
control or one of two distinct MOR23 siRNAs at 24 hr in DM
and RT-PCR was performed; no MOR23 mRNA was observed
with either MOR23 siRNA (Figure S2). Since both MOR23 siRNAs
resulted in similar knockdown, subsequent experiments were
carried out using MOR23 siRNA 3, unless otherwise indicated.
To determine whether expression of other ORs was affected
by MOR23 siRNA, RNA was isolated from cells infected with
control or MOR23 siRNA and Real Time RT-PCR was performed;
no effect on mRNAs for other ORs was observed with MOR23
siRNA (Table S4). By immunoblotting, cells infected with MOR23
siRNA exhibited at least a 58% decrease in MOR23 protein
although some of the residual antibody reactive band could
have been Olfr1403, and hence a greater decrease in MOR23
protein actually occurred (Figure 2C). To determine if MOR23
signaling was abrogated due to MOR23 siRNA, control and
MOR23 siRNA cells were exposed to the synthetic MOR23 ligand
lyral (Fukuda et al., 2004), and the levels of cAMP were detected
by ELISA (Figure 2D). Levels of cAMP were increased 60% in
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A Figure 1. Multiple ORs Are Expressed
During In Vitro Myogenesis and Muscle
Regeneration
Real Time RT-PCR was used to analyze the time
course of expression both in vitro and in vivo for
19 ORs.
(A) During myotube formation the majority of
myoblasts (red) differentiate into myocytes (blue).
Myocytes fuse with one another to form small
nascent myotubes with few nuclei. Subsequently,
nascent myotubes fuse with myocytes to form
large myotubes with many nuclei.
(B) Two patterns of expression were observed
in vitro: peak expression either during proliferation
or after terminal differentiation. Olfr15 and Olfr16
(MOR23) are shown.
(C) The number of ORs with highest expression
levels at each time point in vitro. The majority of
ORs are expressed in proliferating cells at 0 hr in
DM; however, several ORs are also expressed at
24 hr in DM, during the fusion process.
(D) Three patterns were observed in vivo: peak expression in uninjured muscle and increased expression day 5 or day 10 after injury. Olfr15, Olfr16 (MOR23), and
Olfr71 are shown.
(E) The number of ORs with highest expression levels at each time point in vivo. The majority of ORs demonstrated peak expression at day 5 after injury, with few
ORs showing peak expression either earlier or later. All data are mean unless otherwise stated.650 Developmental Cell 17, 649–661, November 17, 2009 ª2009 Elsevier Inc.
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MOR23 Regulates Muscle Cell Adhesion and Migrationcontrol siRNA cells and MOR23 siRNA abrogated this effect,
indicating MOR23 protein levels are significantly decreased in
MOR23 siRNA cells as they do not increase cAMP in response
to lyral.
Subsequently, Boyden chamber experiments were performed
using control and MOR23 siRNA cells with conditioned media
(CM) collected from muscle cells at 24 hr in DM as the chemoat-
tractant (Figure 2E). A 55% decrease in migration to CM was
observed with each MOR23 siRNA. In order to determine if
MOR23 siRNA cells had a general motility defect that could
account for these results, time-lapse microscopy was performed
at 24 hr in DM in regular culture dishes (Figure 2F). MOR23
siRNA did not significantly affect cell velocity when compared
to control siRNA cells. To determine if removal of any OR was
sufficient to alter migration, we focused on the following two
ORs: Olfr1508 and Olfr1403; Olfr1508 was the only OR to share
a similar expression pattern to MOR23, both in vivo and in vitro,
(Figures S3A and S3B), and Olfr1403 has the highest homology
to MOR23. Knockdown of either Olfr1403 (Figure S1D) or
Olfr1508 (Figure S3C) did not affect migration to CM (Figures
S1E and S3D). Hence, decreased migration to CM was specific
to loss of MOR23 and not simply due to loss of any OR.
Migration was also examined in cells expressing recombinant
MOR23. First, to determine whether recombinant MOR23 was
properly trafficked to the plasma membrane, cell surface biotiny-
lation was used. The subsequent biotin pull-down was assayed
for MOR23 by immunoblotting; a 3-fold increase in cell surface
MOR23 was observed (Figure 2G). We performed Boyden
chamber experiments using diluted CM to determine if these
MOR23 overexpressing (OE) cells were more sensitive to CM.
As the CM was diluted, less migration occurred in both control
and MOR23 OE cells; however, the MOR23 OE cells exhibited
higher levels of migration at all dilutions (Figure 2H). Thus,
increasing MOR23 levels alone is sufficient to change the
migratory behavior of myocytes. Together, these data indicate
that MOR23 regulates myocyte migration and suggest that
an endogenous MOR23 ligand is secreted by fusing muscle
cultures.
To discern whether a MOR23 ligand is present in muscle tissue
in vivo, Boyden chamber experiments were performed using
crushed muscle extract (CME). CME resulted in a 9-fold increase
of myocyte migration, which was abrogated in MOR23 siRNA
cells (Figure 2I). In order to test the migration of MOR23 OE cells,
a different optimal concentration of CME was used based on
preliminary dose-response curves. With MOR23 OE a 3-fold
increase in myocyte migration occurred (Figure 2J). These data
suggest that a ligand(s) or its precursor is present within muscle
tissue prior to induction of muscle regeneration.
MOR23 Regulates Directed Migration
The decreased migration of MOR23 siRNA cells to CM likely
results from a defect in directed migration, as no general motility
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Figure 2. MOR23 RegulatesMyocyteMigra-
tion during Myogenesis
(A) Real time RT-PCR indicates MOR23 mRNA
was significantly increased at 24 hr in DM. Data
were normalized to 18S rRNA (*p < 0.05 from 0).
(B) Immunoblots for MOR23 and OR signaling
proteins; Gaolf and membrane adenylyl cyclase III
(mACIII) at 24 hr in DM. Tubulin was used as
a loading control.
(C) Immunoblots indicate MOR23 protein was
decreased at least 58% by MOR23 siRNA.
(D) Myocytes from control or MOR23 siRNA
cultures were treated with lyral and levels of
cAMP were determined (*p < 0.05 from control;
**p < 0.05 from lyral).
(E) Myocytes from control or MOR23 siRNA
cultures were allowed to migrate to conditioned
media. MOR23 siRNA decreased migration by
55% compared to control (*p < 0.05; **p < 0.01
from control).
(F) Myocyte velocity was calculated from 3 hr of
time-lapse microscopy with 20 cells analyzed in
each of three isolates. Minor decreases in velocity
were observed in MOR23 siRNA cultures at 24 hr
in DM.
(G) MOR23 OE cells at 24 hr in DM demonstrated
increased levels of cell surface MOR23 com-
pared to control; immunoblots were performed
after cell surface biotinylation and biotin pull-
down.
(H) Myocytes from control or MOR23 OE cells were allowed to migrate to dilutions of CM. MOR23 OE myocytes exhibited increased migration at all concen-
trations of CM compared to control (*p < 0.05).
(I) Control or MOR23 siRNA myocytes were allowed to migrate in Boyden chambers to CME. Control siRNA myocytes increased migration to CME 2.5-fold, but
MOR23 siRNA myocytes did not (*p < 0.05 from 0).
(J) Control or MOR23 OE myocytes were allowed to migrate in Boyden chambers to CME. Migration of MOR23 OE myocytes to CME was increased 3-fold
compared to control myocytes (*p < 0.05). All data are mean ± SEM.Developmental Cell 17, 649–661, November 17, 2009 ª2009 Elsevier Inc. 651
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MOR23 Regulates Muscle Cell Adhesion and Migrationdefect was observed. To address this question, we used the
Dunn chemotaxis chamber to determine if MOR23 siRNA cells
respond to a gradient of lyral. Time-lapse microscopy was per-
formed for 3 hr, the paths of individual cells tracked, and the final
location of each cell in relation to its origin determined
(Figure 3A). Myocytes migrated toward lyral, yielding migration
paths that ended on the lyral side of the chamber. To statistically
analyze the pattern of migratory paths in response to lyral, direc-
tional data were summarized in circular histograms. Rayleigh’s
statistical test for clustering revealed that control cells (Fig-
ure 3B), but not MOR23 siRNA cells (Figure 3C), migrated toward
lyral. A rescue experiment in which myocytes expressed both
MOR23 siRNA and recombinant MOR23 (Figure S4) demon-
strated directed cell migration toward lyral (Figure 3D), indicating
that migration to lyral is specific to MOR23. To determine
whether migration toward lyral requires mACIII, an inhibitor of
membrane adenylyl cyclases, SQ22536, was used (Figure S5).
Addition of the mAC inhibitor abrogated migration toward lyral
(Figure 3E), indicating that canonical OR signaling is used in
lyral-directed migration. As a control, to determine if lyral-depen-
dent migration was specific to MOR23, myoblasts which express
the highly homologous Olfr1403 and the lyral-responsive Olfr15
(Saito et al., 2009) but not MOR23, were tested in Dunn cham-
bers. These cells did not undergo directed migration toward
107 M lyral (Figure 3F). In addition, knockdown of Olfr1403 or
Olfr1508 in myocytes did not affect migration to lyral (Figures
S1F and S3E), revealing that migration of myocytes to lyral is
specific to MOR23 and occurs in a directed manner.
Loss of MOR23 Alters Cell-Cell Adhesion
Recent evidence suggests that ORs may regulate axon guidance
of olfactory neurons via downstream changes in the expression
of cell-cell adhesion molecules (Serizawa et al., 2006). To
determine whether loss of MOR23 alters cell adhesion, a solu-
tion-based cell adhesion assay was utilized in which control or
MOR23 siRNA myocytes were suspended in media and aliquots
taken over 60 min to count the number of adhered and unadhered
cells using phase-contrast microscopy. Myocytes infected with
MOR23 siRNA did not efficiently adhere to one another
(Figure 4A). Although no difference in adhesion was observed
at early time points, at later time points, a significant increase
occurred in unadhered MOR23 siRNA cells (Figure 4B). At later
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Figure 3. MOR23 Regulates Directed Migration of Myocytes to Lyral
(A) Migratory paths of myocytes tracked for 3 hr with pictures every 5 min in
a representative Dunn chamber experiment with 15–20 cells in each graph.
Lyral gradient was highest at left side.
(B–F) Circular histogram plots summarizing Dunn chamber data from 3–5
independent cell isolates with 15–20 cells analyzed in each experiment. Lyral
gradient was highest at left side. Red line and arc indicate the mean direction
and 99% confidence interval for conditions in which significant clustering of
cell migration occurred.
(B and C) Control cells exhibited directed migration to lyral which was
abolished in MOR23 siRNA cells.
(D) Migration to lyral is MOR23-specific as MOR23 siRNA cells rescued by
MOR23 OE exhibited directed migration.
(E) Migration is dependent on membrane adenylyl cyclase function as inhibitor
SQ22536 abrogated directed migration to lyral.
(F) Myoblasts, which express Olfr1403 but not MOR23, did not exhibit directed
migration toward lyral.652 Developmental Cell 17, 649–661, November 17, 2009 ª2009 Elsevier Inc.
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MOR23 Regulates Muscle Cell Adhesion and Migrationtimes, MOR23 siRNA cells remained in small clusters compared
to control siRNA cells (Figure 4C). Cell viability was 99% at
60 min in all conditions (data not shown). Canonical OR signaling
is also necessary for axonal migration and adhesion (Imai et al.,
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Figure 4. Loss of MOR23 or OR Signaling Alters Cell-Cell Adhesion
(A) Myocytes infected with control or MOR23 siRNA were incubated in suspen-
sion for 60 min with aliquots taken regularly, to determine the percentage of
unadhered and adhered cells by phase-contrast microscopy (Bar = 50 mm).
(B) MOR23 siRNA cells displayed a significantly higher percentage of unad-
hered cells at later time points than control (*p < 0.05).
(C) MOR23 siRNA cells exhibited fewer clusters with >5 cells (*p < 0.05).
(D) Myocytes were suspended in media containing a mAC inhibitor, SQ22536,
or vehicle (Bar = 50 mm).
(E) SQ22536-treated cells displayed a significantly higher percentage of unad-
hered cells at later time points (*p < 0.05).
(F) SQ22536-treated cells formed small clusters (*p < 0.05). All data are mean ±
SEM.Developme2006), and to determine whether it regulates cell-cell adhesion
of myocytes, cells were treated with mAC inhibitor SQ22536, or
vehicle (Figure 4D). At early time points, no difference was
observed, however at later time points a significant increase
occurred in unadhered cells with SQ22535 (Figure 4E). Further-
more, SQ22536-treated cells formed smaller clusters than
vehicle (Figure 4F). Knockdown of Olfr1403 or Olfr1508 did not
affect adhesion (Figures S1G and S3F). Hence, adhesion effects
were specific to loss of MOR23 and not simply due to loss of any
OR. Together, these data suggest that MOR23 signaling affects
adhesion of myocytes toone another likely through a downstream
adhesion molecule.
Myotube Formation Is Dependent on MOR23
To test whether MOR23-dependent migration and/or adhesion is
involved in muscle cell differentiation or fusion, we examined
myogenesis in vitro in cells containing one of two MOR23
siRNAs. After 24 or 48 hr in DM, cells were immunostained using
an antibody against embryonic myosin heavy chain (eMyHC).
After 24 hr in DM, both MOR23 siRNA cultures contained
fewer and smaller nascent myotubes compared to control
(Figure 5A). This defect in myotube formation was not due to
an effect on differentiation, as measured by the percentage of
nuclei found in eMyHC+ cells (Figure 5B), nor to a decrease in
the total number of nuclei (data not shown). Rather, MOR23
siRNA myocytes exhibited a clear defect in cell fusion (Figures
5C–5E). The fusion index, as well as the number of myotubes,
was transiently decreased 33% and 26%, respectively, in
MOR23 siRNA cultures (Figures 5C and 5D). A 15% decrease
in myonuclear number was also noted at 24 hr in DM in
MOR23 siRNA cultures, which remained virtually unchanged at
48 hr (Figure 5E) and 72 hr (data not shown). The transient fusion
defects in MOR23 siRNA cultures may be due to compensation
from other factors which regulate fusion.
To determine whether the impaired ability of MOR23 siRNA
cultures to fuse is specific to the loss of MOR23, assays using
MOR23 OE were also performed. MOR23 OE resulted in an
increased number of nascent myotubes at 24 hr in DM
(Figure 5F), with no change in differentiation (Figure 5G). Fusion
assays revealed a 30% increase in the fusion index and a 40%
increase in the number of myotubes at 24 hr in DM, with smaller
increases in both parameters still noted at 48 hr and 72 hr
(Figures 5H and 5I and data not shown). Myonuclear number
was also increased 10% at both time points in MOR23 OE
cultures (Figure 5J). Together these data suggest that MOR23-
dependent migration and/or adhesion contributes to the fusion
of myocytes to form nascent myotubes.
Changes in myonuclear number with MOR23 siRNA or OE at
48 hr suggest that MOR23-dependent migration and/or adhe-
sion may also regulate formation of mature myotubes from fusion
of myocytes with nascent myotubes. Since the formation of
nascent myotubes was effected in previous assays, we could
not independently determine a role for MOR23 in this later stage
of fusion. To analyze if MOR23 affects the fusion of myocytes
with nascent myotubes (Figure 1A), control and MOR23 siRNA
nascent myotubes and myocytes were created separately,
labeled with green or orange fluorescent dye, cocultured for
24 hr (Figure 5K), and the number of dual labeled myotubes
was quantified. With MOR23 siRNA in myocytes the percentagental Cell 17, 649–661, November 17, 2009 ª2009 Elsevier Inc. 653
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Figure 5. Myotube Formation Is Regulated by MOR23
(A) Control or MOR23 siRNA 2 and 3 cells immunostained for eMyHC at 24 hr in DM (Bar = 50 mm).
(B) No difference was observed in the percentage of nuclei in eMyHC+ cells at 24 hr in DM (differentiation index).
(C) The fusion index in MOR23 siRNA cultures was transiently decreased at 24 hr in DM (*p < 0.001).
(D) The number of myotubes in MOR23 siRNA cultures was transiently decreased at 24 hr in DM (*p < 0.001).
(E) Myonuclear number in MOR23 siRNA cultures was decreased at both 24 and 48 hr in DM (*p < 0.05; **p < 0.01).
(F) Control (C) or MOR23 OE (M) cells were immunostained for eMyHC at 24 hr in DM (Bar = 50 mm).
(G) No difference was observed in the percentage of nuclei in eMyHC+ cells at 24 or 48 hr in DM.
(H) The fusion index in MOR23 OE cultures was increased at 24 and 48 hr in DM (*p < 0.05; **p < 0.01).
(I) The number of myotubes in MOR23 OE cultures was increased at 24 and 48 hr in DM (*p < 0.05; **p < 0.01).
(J) Myonuclear number in MOR23 OE cultures was increased at 24 and 48 hr in DM (*p < 0.01).
(K) Nascent myotubes infected with control or MOR23 siRNA were labeled orange and mixed with control or MOR23 siRNA myocytes labeled green. After 24 hr of
coculture, cultures were fixed and myotubes analyzed for dual labeling.654 Developmental Cell 17, 649–661, November 17, 2009 ª2009 Elsevier Inc.
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MOR23 Regulates Muscle Cell Adhesion and Migrationof myotubes with dual label was decreased 20% compared to
control (Figure 5L), whereas MOR23 siRNA in myotubes had
no effect on dual labeling. To determine whether increased
expression of MOR23 on myocytes could enhance fusion,
control or MOR23 OE myocytes were cocultured with control
nascent myotubes (Figure 5M). MOR23 OE in myocytes
increased dual labeling 35% (Figure 5N), indicating MOR23
expression on myocytes alone is sufficient to increase fusion of
myocytes with nascent myotubes. Together, these data indicate
that MOR23 is functionally required on myocytes. Therefore,
MOR23-dependent processes can affect myonuclear addition
at later stages of myogenesis.
MOR23 Regulates Myogenesis In Vivo
To determine the detailed expression pattern of MOR23 during
adult regenerative myogenesis, RNA was isolated from mouse
gastrocnemius muscles at different times after injury. Using
Real Time RT-PCR, MOR23 mRNA was induced 4-fold during
days 3–7 postinjury (Figure 6A), a time of extensive cell fusion.
By 14 days postinjury, when regeneration is nearly complete,
MOR23 mRNA levels had returned to uninjured control levels.
MOR23 protein levels were increased at day 5 postinjury,
a time when fusion is ongoing and nascent myofibers are
present, as determined by immunoblot (Figures 6B and 6G).
Olfr1403 mRNA was not increased during muscle regeneration
at these times (Figure S1C). Sections from gastrocnemius
muscles at day 5 postinjury were immunostained with an anti-
body against MOR23 (Figure 6C). Regenerating myofibers, iden-
tified by their centrally located nuclei and small size, contained
MOR23. To determine whether mononucleated muscle cells
express MOR23 during regeneration, cells were isolated from
regenerating muscle and myogenic cells (a7-integrin+CD31
CD45, Kafadar et al., 2009) were separated from immune and
endothelial cells (a7-integrinCD31+CD45+) by FACS (Figure S6).
Real Time RT-PCR revealed expression of MOR23 mRNA in
a7-integrin+CD31CD45 cells, which also expressed myogenin
mRNA, confirming their myogenicity (Figure 6D). MOR23 mRNA
was not apparent in the a7-integrinCD31+CD45+ fraction; this
fraction did express Mac1 mRNA, suggesting many of these
cells are immune cells. Furthermore, immunostaining for MOR23
in a7-integrin+CD31CD45 cells indicated 86% of muscle
cells express MOR23 (Figure 6E). The myogenic purity of these
cells was >99% as determined by the expression of Myf5.
Thus, MOR23 expression is induced in myogenic cells during
muscle regeneration when myofibers are forming. Overall these
data suggest that the induction of MOR23 expression may be
tied to migration and/or adhesion events that occur during cell
fusion in muscle regeneration.
To analyze MOR23 function during muscle regeneration,
gastrocnemius muscles were induced to regenerate with BaCl2
2 days prior to electroporation of either MOR23 siRNA or OE
plasmids. Induction of regeneration allowed myoblasts to take
up plasmid, as determined in preliminary experiments. Gastroc-
nemius muscles were isolated 5, 10, or 20 days postelectropora-Developmtion (Figure 6F). Knockdown of MOR23 protein was determined
by immunoblot at day 5, and an 85% reduction of MOR23 was
observed (Figure 6G), suggesting that the majority of the immu-
noreactive band is MOR23 and not Olfr1403. Although little to no
difference existed in proliferation or differentiation in muscles
that received MOR23 siRNA compared to control (Figure S7),
abnormalities in muscle regeneration were noted in MOR23
siRNA muscles at all time points (Figure 6H). The mean cross-
sectional area (XSA) of regenerating myofibers in MOR23 siRNA
muscles was decreased 26%–38% (Figure 6I) with a corre-
sponding 30% increase in the number of myofibers smaller
than 1500 mm2 at day 20 (Figure 6J). In addition, the number of
regenerating myofibers per field increased 50% with MOR23
siRNA (Figure 6K). In contrast, MOR23 OE in vivo resulted in
a 5-fold increase in MOR23 mRNA (Figure S8), and increased
myofiber XSA 50% (Figure 6L), with a corresponding 39%
decrease in the number of myofibers smaller than 1500 mm2 at
day 20 (Figure 6M). In addition, the number of regenerating
myofibers per field decreased 21%–36% with MOR23 OE
(Figure 6N). These data suggest that optimal muscle regenera-
tion is dependent on MOR23.
MOR23 Affects Myofiber Branching In Vivo
Small clusters of myofibers in MOR23 siRNA muscles were
observed, which suggested that myofiber branching may have
occurred with loss of MOR23. Myofiber branching is character-
ized by a single myofiber having a plasma membrane contiguous
with several smaller myofibers (Figure 7A). Myofiber branching is
an important phenomenon, as it is increased with multiple
injuries, aging, and muscular dystrophy (Ontell et al., 1982).
The molecules which regulate this process are unknown,
although cell-cell adhesion molecules are hypothesized to play
a role fusing branched myofibers to form mature myofibers.
We hypothesized that the increase in small myofibers observed
in MOR23 siRNA muscles may be due to an increase in unre-
solved myofiber branches, yielding the appearance of many
small myofibers rather than large myofibers apparent in control
siRNA muscles. To determine whether MOR23 may regulate
myofiber branching, cross-sections 170 mm apart were isolated
from gastrocnemius muscles 5 days after electroporation.
Myofiber branching was quantified by determining the number
of regenerating myofibers that were a single myofiber in one
section and multiple fibers occupying the same area in a second
section (Figure 7B). Muscles with MOR23 siRNA exhibited a 40%
increase in the percentage of branching myofibers (Figure 7C),
and more branches per myofiber (Figure 7D). MOR23 OE did
not result in changes in myofiber branching at day 5 (Figure 7E).
In order to visualize the entire myofiber, single myofibers were
isolated to determine the extent of branching. We were unable
to isolate intact regenerating myofibers at day 5; however, myo-
fiber branches could be visualized at days 10 and 20 using
phase-contrast microscopy and DAPI-staining was used to
identify regenerating myofibers by the presence of centrally
located nuclei (Figure 7F). Myofibers with multiple tracks of(L) With MOR23 siRNA in myocytes the percentage of myotubes with dual label was decreased 20% relative to control; however, MOR23 siRNA in myotubes had
no effect (*p < 0.001).
(M) Control nascent myotubes were mixed with control or MOR23 OE myocytes and analyzed as in (K).
(N) With MOR23 OE in myocytes, the percentage of myotubes with dual label was increased 35% relative to control (*p < 0.05). All data are mean ± SEM.ental Cell 17, 649–661, November 17, 2009 ª2009 Elsevier Inc. 655
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MOR23 Regulates Muscle Cell Adhesion and Migrationcentral nuclei, but unbranched cytoplasm, are mature regener-
ated myofibers (Figure 7F, arrowheads). Muscles electroporated
with MOR23 siRNA exhibited a 60% increase in regenerating
myofibers with branches (Figure 7G) and 90% more branches
per myofiber (Figure 7H). In contrast, a 50% decrease in the
number of branched myofibers (Figure 7I) occurred in MOR23
OE muscles at day 20 with 70% fewer branches per myofiber
(Figure 7J). These data suggest that myofiber branching is regu-
lated by MOR23, possibly through its effects on migration and
adhesion of muscle cells.
DISCUSSION
In many systems, tissue repair requires cell migration and adhe-
sion. Our results suggest these processes are also necessary for
proper regeneration of muscle tissue. We show multiple ORs are
expressed by muscle cells during myogenesis in vitro and
muscle regeneration in vivo. In depth studies on one of these
ORs, MOR23, revealed a role in regulating migration and adhe-
sion of muscle cells, which are critical for cell fusion. Importantly,
these studies identify an unexpected functional role for MOR23
in skeletal muscle regeneration, demonstrating a novel function
for an OR in tissue repair.
MOR23 was expressed by terminally differentiated myocytes
in vitro, functioning to regulate their migration. Interestingly,
MOR23 also regulates migration of mouse sperm in vitro (Fukuda
et al., 2004) and ORs are hypothesized to play a role in axonal
growth cone migration (Feinstein et al., 2004), suggesting that
MOR23 has a conserved function in migration of multiple cell
types. Although synthetic ligands are known for many odorant
receptors, endogenous ligands have not been identified. Both
CME and CM contained a ligand that stimulated myocyte migra-
tion in a MOR23-dependent manner. CME was prepared from
uninjured muscle tissue, which indicates that the MOR23 ligand
is present prior to the onset of muscle injury. The ligand may be
present in an inactive form in normal muscle tissue and become
activated by the ‘‘crushing’’ used in preparing CME. In vivo, HGFDevelopmis expressed in an inactive form, which is expressed by muscle
cells and then bound by the extracellular matrix until matrix met-
alloproteases cleave and release the active form (Allen et al.,
2003). Alternatively, the ligand may be stored within myofibers
and released upon myofiber degeneration. CM collected from
differentiating muscle cultures in vitro also contained the
MOR23 ligand, demonstrating that muscle cells themselves
can be the source of the ligand. These results do not rule out
that other cell types may also express the MOR23 ligand
in vivo. Preliminary data indicate the MOR23 ligand is likely not
sensitive to heat or Proteinase K digestion (data not shown).
Identification of sources for the MOR23 ligand will allow future
purification of an endogenous OR ligand from a readily available
source, as opposed to follicular fluid, which is the only other
hypothesized source of an endogenous OR ligand (Spehr and
Hatt, 2004). If the ligand for MOR23 can be isolated, it may
give insight into the nature of endogenous ligands for other
odorant receptors, including the human odorant receptor found
in sperm.
MOR23 also regulated cell-cell adhesion, indicating another
conserved function for ORs between muscle and olfactory
neurons. In olfactory neurons, OR signaling is required for
expression of adhesion molecules, which correlates with altered
axon guidance into specific glomeruli (Imai et al., 2006).
However, changes in the adhesiveness of the olfactory neurons
were not assayed. In contrast, we performed adhesion assays
which demonstrated that loss of MOR23 or OR signaling
decreased cell-cell adhesion, suggesting that MOR23 regulates
adhesion indirectly, possibly through regulating expression of
specific downstream adhesion molecules. Further studies are
needed to determine which adhesion molecules may be affected
by MOR23 signaling.
MOR23 expression was induced with muscle regeneration
and manipulating the levels of MOR23 affected several aspects
of muscle regeneration, including myofiber cross-sectional area,
number, and branching. Although branched myofibers have
been noted in the literature for 100 years (Schmalbruch, 1976;Figure 6. Changes in MOR23 Expression Affect Muscle Regeneration
(A) Real Time RT-PCR for MOR23 mRNA in gastrocnemius muscles at different times postinjury. All days are normalized to 18S rRNA and expressed as fold
increase over 0 days (*p < 0.01).
(B) Immunoblot for MOR23 at 0 and 5 days with a portion of the Ponceau-stained blot shown as control.
(C) Muscles 5 days postinjury immunostained for MOR23 or control IgG (Bar = 25 mm). MOR23+ regenerating myofibers are shown at higher magnification in last
panels (Bar = 10 mm). Overlay in bottom panels indicates DAPI-stained nuclei.
(D) Mononucleated cells were isolated from gastrocnemius muscles 5 days postinjury and immunostained with antibodies to CD31 (FITC), CD45 (FITC), and
a7-integrin (PE): CD31+CD45+, to identify endothelial and immune cells and a7-integrin+CD31CD45 for myogenic cells. Real Time RT-PCR for MOR23,
myogenin (Myg), and Mac1 mRNA in a7-integrin+CD31CD45 cells or a7-integrinCD31+CD45+ cells. All genes are normalized to 18S rRNA and expressed
as mean pg of RNA from N = 2; 7 mice each.
(E) Mononucleated a7-integrin+CD31CD45 muscle cells isolated from gastrocnemius muscles 5 days postinjury, were plated and immunostained for MOR23.
A single MOR23+ cells is shown at higher magnification in right panel (Bars = 10 mm).
(F) Gastrocnemius muscles were induced to regenerate using BaCl2 2 days prior to electroporation of control or MOR23 plasmids. Muscles were isolated 5, 10, or
20 days postelectroporation; uninjured muscles were collected from contralateral day 20 legs.
(G) Immunoblot demonstrating knockdown of MOR23 protein at day 5 with section of Ponceau-stained blot shown as control.
(H) Control or MOR23 siRNA muscles stained with hematoxylin and eosin (Bar = 100 mm).
(I) The XSA of regenerating myofibers was decreased with MOR23 siRNA (*p < 0.05 from control, # p < 0.05 from uninjured).
(J) The frequency of small regenerating myofibers increased with MOR23 siRNA.
(K) The number of regenerating myofibers increased with MOR23 siRNA (*p < 0.05 from control, # p < 0.05 from uninjured).
(L) The XSA of regenerating myofibers was increased with MOR23 OE (*p < 0.05 from control, # p < 0.05 from uninjured).
(M) The frequency of small regenerating myofibers decreased with MOR23 OE.
(N) The number of regenerating myofibers decreased with MOR23 OE (*p < 0.05 from control, # p < 0.05 from uninjured). All data are mean ± SEM unless stated
otherwise.ental Cell 17, 649–661, November 17, 2009 ª2009 Elsevier Inc. 657
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MOR23 Regulates Muscle Cell Adhesion and MigrationVolkmann, 1893), no molecule is known to regulate their forma-
tion. We show that loss of MOR23 increased myofiber branch-
ing. Expression of MOR23 by mononucleated muscle cells and
regenerating myofibers in vivo suggests both migration and
adhesion could contribute to these effects. If myocyte migration
is required for fusion with existing regenerating myofibers, then
defects in migration would increase the formation of de novo my-
ofibers. Alternatively, formation of small myofibers may normally
occur, which adhere to one another, and then fuse to form larger
myofibers, and when adhesion is disrupted, branched myofibers
occur. Therefore, loss of MOR23 may disrupt myofiber formation
on several levels. Since muscles containing unbranched myofib-
ers are stronger than those with extensive branching (Chan et al.,
2007) and MOR23 OE can decrease the occurrence of branch-
ing, MOR23 may be an important target for therapies directed
at increasing strength of dystrophic muscle.
As MOR23 functions in the repair of skeletal muscle, and
multiple ORs are expressed during myogenesis, other ORs
may regulate similar or distinct processes. Recent evidence
suggests that activation of an OR inhibits proliferation of prostate
cancer cells (Neuhaus et al., 2009), therefore, ORs that were up-
regulated in myoblasts may regulate proliferation. Also, as
muscle cells must interact directly with one another for terminal
differentiation to occur (Krauss et al., 2005), ORs in addition to
MOR23 may play a role in the migration or adhesion of these
cells. As Olfr49 was expressed only in muscle tissue, other cell
types present in muscle, such as immune cells, endothelial cells,
fibroblasts, or neurons may also express ORs. Finally, ORs
present in uninjured muscle or at later time points in regeneration
may be necessary for quiescent satellite cells, either to keep
these cells in their niche or to affect their proliferation state.
Our data suggest that multiple ORs may regulate myogenesis,
and therefore, may be necessary for proper tissue repair. Addi-
tional studies will be necessary to determine the specific effects
of each of these ORs both in vitro and in vivo.
Interestingly, in the olfactory neuron field, only one OR is ex-
pressed in each cell (Touhara et al., 1999). As multiple ORs
were expressed by muscle cultures, subpopulations of muscle
cells may each express a single OR. Potentially the ‘‘one cell,
one OR’’ hypothesis may not hold true for muscle cells, and
several ORs are expressed by each muscle cell. A redundant
system may exist, so that even if one OR signal is somehow
blocked, other ORs may substitute. Alternatively, cells express-
ing multiple ORs may utilize specific ORs in a spatial-temporal
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Figure 7. MOR23 Regulates Myofiber
Branching
(A) Schematic of myofiber branching in which
a single myofiber is contiguous with several
smaller myofibers. Nuclei are blue and mononu-
cleated cells are small red circles.
(B) Gastrocnemius muscles isolated 5 days after
electroporation of plasmid were analyzed for myo-
fibers that were a single myofiber in one section
and multiple myofibers occupying the same area
in a second section, 170 mm away. Stars indicate
the same myofiber in both sections; a branched
myofiber is circled (Bar = 50 mm).
(C) Myofiber branching was increased with
MOR23 siRNA (*p < 0.05).
(D) The number of branches per myofiber increased
with MOR23 siRNA. Data are percentage of total
myofibers.
(E) Myofiber branching was not affected at day 5
with MOR23 OE.
(F) Myofibers were isolated from gastrocnemius
muscles 10 or 20 days after electroporation of
plasmid. DAPI-stained centrally located nuclei
and phase-contrast microscopy determined if
regenerating myofibers exhibited branching.
Arrows indicate a branched regenerating myo-
fiber, arrow-head an unbranched regenerating
myofiber (Bar = 50 mm).
(G) Muscles with MOR23 siRNA contained more
branched regenerating myofibers. Data are
percentage of total myofibers.
(H) The number of branches per myofiber
increased with MOR23 siRNA. Data are
percentage of total myofibers.
(I) Muscles with MOR23 OE contained fewer
branched regenerating myofibers. Data are
percentage of total myofibers.
(J) The number of branches per myofiber
decreased with MOR23 OE. All data are mean ±
SEM unless stated otherwise.658 Developmental Cell 17, 649–661, November 17, 2009 ª2009 Elsevier Inc.
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MOR23 Regulates Muscle Cell Adhesion and Migrationmanner. Additional studies may elucidate whether multiple pop-
ulations of muscle cells each express a single OR, or whether
each muscle cell expresses several ORs.
In summary, MOR23 is a key regulator of myogenesis through
its actions on cell migration and adhesion, affecting downstream
fusion in vitro and muscle regeneration in vivo. Cell migration
within muscle is a major issue in transplantation of cells for treat-
ment of muscular dystrophy (Skuk and Tremblay, 2003; Smythe
et al., 2001). Study of the receptor-ligand pairs that regulate
migration and/or adhesion of muscle cells may allow for more
efficient therapeutic strategies. In addition, further studies on
ORs may reveal additional unexpected functions in various
tissues.
EXPERIMENTAL PROCEDURES
Animals and Muscle Injuries
Adult mice between 8–24 weeks of age were used and handled in accordance
with the IACUC guidelines of Emory University. To induce regeneration,
gastrocnemius muscles of male C57BL/6 mice were injected with BaCl2
(O’Connor et al., 2007) and collected as described (Abbott et al., 1998).
Primary Muscle Cell Culture, Differentiation, and Fusion Assays
Primary myoblasts were derived from the hindlimb muscles of Balb/C mice
and cultures were >99% myogenic as assessed by MyoD immunostaining
(Jansen and Pavlath, 2006). To induce differentiation, cells were switched
to DM, immunostained with an eMyHC antibody (F1.652; Developmental
Studies Hybridoma Bank), and analyzed as described (Jansen and Pavlath,
2006). At least 500 nuclei per condition were analyzed for each assay. Cell
mixing experiments were performed as described (Jansen and Pavlath,
2006). The presence of dual label was analyzed in 50–100 myotubes
with R3 nuclei in each experiment. For all experiments 3–6 independent
isolates were analyzed.
Plasmid Production and Retroviral Infection
Oligonucleotides (Supplemental Experimental Procedures) encoding siRNA
to MOR23 were cloned into the retroviral plasmid pSUPER.retro.puro
according to OligoEngine protocol. The control plasmid contained a scrambled
siRNA sequence. Retroviral production and infection were performed as
described (Abbott et al., 1998) and cells were used 48 hr later in experiments.
The efficiency of retroviral-mediated gene transfer was >95%, based on cell
survival in the presence of puromycin following two rounds of retroviral
infection.
To generate a MOR23 retroviral expression vector, a cDNA fragment encod-
ing a FLAG-Rho-MOR23 was subcloned from the pME18S construct (Katada
et al., 2003) into the retroviral vector pTJ84 using the AvrII and SalI/XhoI sites
(Abbott et al., 2000). pTJ84 was used as the control vector.
Real-Time RT-PCR
Real-time RT-PCR was performed on DNase treated total RNA, reverse tran-
scribed to cDNA, amplified using primers from SABiosciences, and analyzed
using the iCycler iQ Real-Time Detection System and software (Bio-Rad)
as described (Bondesen et al., 2004). For conditions and controls, see the
Supplemental Experimental Procedures. MOR23 mRNA was quantified in
reference to MOR23-pME18S plasmid standard and normalized to 18S
rRNA levels.
Immunoblotting
Cells were harvested in RIPA-2 (O’Connor et al., 2007) with protease inhibitors
(Mini-Complete; Roche) and immunoblots were performed as described
(Friday and Pavlath, 2001) with primary antibodies (a-MOR23, GeneTex;
a-Golf, a-mACIII, and a-tubulin, Abcam, Inc.) and detected with appropriate
secondary HRP-conjugated antibodies (Jackson ImmunoResearch Lab., Inc.).
Cell surface biotinylation was performed as described (Salazar and Gonza-
lez, 2002). Sulfo-NHS-SS-Biotin was used at 500 mM (Pierce) and protein wasDevelopmisolated in RIPA-2. Immunoprecipitation was performed with NeutrAvidin
Agarose Resins (Pierce) with 300 mg of protein at 4C overnight.
cAMP Assay
cAMP was detected using the CatchPoint kit from Molecular Probes. Myo-
cytes were generated as for Boyden chambers and plated in 96-well plates
at 13 105 cells/well. Cells were treated with either buffer or 104 M lyral (Inter-
national Flavors and Fragrances) for 15 min in triplicate.
Cell Migration and Adhesion Assays
Migration of muscle cells was quantified using time-lapse microscopy as
described (Jansen and Pavlath, 2006). Images were recorded (QImaging
Camera and OpenLab 3.1.4 software) every 5 min for 3 hr. Cell velocities
were calculated in mm/hr using ImageJ software by tracking the paths of
mononucleated cells. Approximately 20 mononucleated cells were tracked
for each experiment. Boyden chambers were performed as described (Mylona
et al., 2006). Primary myoblasts were seeded on 150 mm plates at low density
(93 105 cells/plate) and switched to DM for 24 hr to generate myocytes in the
absence of myotube formation. Cells (7.53 104 cells in 200 ml DM) were loaded
in the upper wells of the Boyden chamber and incubated at 37C for 5 hr.
Migrated cells were fixed, stained, and counted. To prepare CM, myoblasts
were incubated in DM for 24 hr; the media, which had been ‘‘conditioned’’
with secreted factors, was then collected, filtered (0.45 mm), flash frozen,
and stored at 80C until use. Crushed muscle extract was created as
described (Chen and Quinn, 1992) using gastrocnemius muscles from
C57BL/6 mice (N = 10) and stored at 80C.
Dunn chambers were performed as described (Jansen and Pavlath, 2006).
The outer well of the Dunn chamber was filled with DM or 107 M lyral in
DM. SQ22536 (Sigma) was used at 2.5 mM. Directional analyses were per-
formed using at least 15 cells per assay.
Cell-cell adhesion in suspension was analyzed by incubating myocytes at
2 3 105 cells in 2 mL of DM after lifting using Cell Dissociation Buffer
Enzyme-Free PBS-Based (Invitrogen). SQ22536 was used at 2.5 mM. Dupli-
cate 50 ml aliquots of cells were taken at regular intervals for 60 min. This
cell concentration was used to permit counting of individual cells within clus-
ters using phase-contrast microscopy. Trypan blue staining was used at
60 min to determine cell viability.
Flow Cytometry
FACS was performed as described (Kafadar et al., 2009) using cells isolated
from day 5 regenerating gastrocnemius muscles. Cells were sorted using
a BD FACSVantage SE and placed into Trizol Reagent (Invitrogen) for RNA
isolation or plated for immunostaining. For detailed methods, see Supple-
mental Experimental Procedures.
Immunostaining
MOR23 immunostaining was performed on muscle sections or muscle cells
isolated by flow cytometry from gastrocnemius muscles 5 days postinjury.
After blocking, sections and cells were incubated overnight at 4C with
MOR23 antiserum or purified rabbit IgG (Genetex Inc.) diluted 1:100 in block-
ing buffer. Immunostaining was visualized using the TSA Rhodamine Tyramide
Signal Amplification kit (PerkinElmer). Nuclei were counterstained with 25 mM
4,6-diamidino-2-phenylindole in 0.1% BSA. For detailed methods, see
Supplemental Experimental Procedures.
In Vivo Electroporation
Gastrocnemius muscles of C57BL/6 mice were injected with BaCl2 to induce
muscle regeneration. Two days later the muscles were injected with the indi-
cated plasmid (25 mg DNA; 1 mg/mL in PBS) and electroporated as described
(O’Connor et al., 2007). Postelectroporation, muscles were collected and
homogenized in RIPA-2 for protein isolation or frozen and sectioned as
described (Abbott et al., 1998). Single myofibers were isolated from previously
injured and electroporated gastrocnemius muscles as described (Kafadar
et al., 2009). Serial 14 mm cross-sections were stained with hematoxylin and
eosin and analyzed by quantifying myofiber number and XSA for three
307,200 mm2 fields in the core of each regenerating muscle (O’Connor
et al., 2007). In preliminary experiments, electroporation of a lacZ plasmid
was utilized to determine efficiency of gene delivery to MyoD+ cells in theental Cell 17, 649–661, November 17, 2009 ª2009 Elsevier Inc. 659
Developmental Cell
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All analysis were performed blinded with N = 4–8 mice per condition and
90–100 myofibers per mouse.
Statistics
To determine significance between two groups, comparisons were made
using Student’s t tests or the Mann Whitney test (in vivo). Analyses of multiple
groups were performed using a one-way or two-way analysis of variance with
Bonferroni’s posttest as appropriate. Statistical analyses were performed
using GraphPad Prism 4.0 (GraphPad). For all statistical tests, a confidence
interval of p < 0.05 or less was accepted for statistical significance.
SUPPLEMENTAL DATA
Supplemental Data include four tables, eight figures, and Supplemental Exper-
imental Procedures and can be found with this article online at http://www.cell.
com/developmental-cell/supplemental/S1534-5807(09)00386-4/.
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